Literature DB >> 6751026

Antihypertensive effects at rest and during exercise of a calcium blocker, nifedipine, alone and in combination with metoprolol.

L G Ekelund, C Ekelund, S Rössner.   

Abstract

The effects of metoprolol and/or nifedipine on blood pressure were studied in 12 hypertensive males at rest and during standardized exercise on an ergometer bicycle. Metoprolol (100 mg X 2) and nifedipine (10 mg X 3) gave similar blood pressure reductions both at rest and during exercise. When the drugs were combined, the antihypertensive effect was potentiated. The PQ interval was not affected during any treatment period. No adverse reactions to the combined treatment were noted. The combination of a calcium blocker with vasodilating properties with a beta-blocker, which reduces cardiac output, thus seems a logical and promising therapeutic approach in the treatment of hypertension.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6751026     DOI: 10.1111/j.0954-6820.1982.tb03172.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  8 in total

Review 1.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

Review 2.  Calcium channel antagonism and beta blockade in combination--a therapeutic alternative in cardiovascular disorders. A review.

Authors:  J N Lessem; B N Singh
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

Review 3.  Metoprolol: a pharmacoeconomic and quality-of-life evaluation of its use in hypertension, post-myocardial infarction and dilated cardiomyopathy.

Authors:  D H Peters; P Benfield
Journal:  Pharmacoeconomics       Date:  1994-10       Impact factor: 4.981

Review 4.  Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders.

Authors:  D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

5.  Effects of treatment with nifedipine and metoprolol in essential hypertension.

Authors:  R Eggertsen; L Hansson
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 6.  Calcium antagonists and exercise performance.

Authors:  W Kindermann
Journal:  Sports Med       Date:  1987 May-Jun       Impact factor: 11.136

7.  Effects of BAY l 5240, a fixed combination of low dose nifedipine and acebutolol on hypertension: comparison with standard dose nifedipine.

Authors:  P Lejeune; W Gunselmann; L Hennies; K Hess; K Rittgerodt; K Winn; G Gfrerer; U Schreiber
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 8.  Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders.

Authors:  P Benfield; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1986-05       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.